Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

Delayed Quote. Delayed  - 09/28 03:36:21 pm
5152 GBp   +1.86%
02:41p WHAT PFIZER INC : PFE) Licensing Deal With OncoImmune, Inc. Means Fo..
02:38p Insmed Appoints Roger Adsett as Chief Commercial Officer
08:05a ASTRAZENECA : 28 September 2016 Professor David Goldstein to lead As..
News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
02:41p WHAT PFIZER INC. (NYSE : PFE) Licensing Deal With OncoImmune, Inc. Means For Age..
02:38p Insmed Appoints Roger Adsett as Chief Commercial Officer
08:05a ASTRAZENECA : 28 September 2016 Professor David Goldstein to lead AstraZeneca&rs..
08:01a ASTRAZENECA : Change to astrazeneca board of directors
09/26 ASTRAZENECA : Innovative pancreatic research expands treatment horizons for peop..
09/23 ASTRAZENECA : Unique molecular atlas of pancreas produced
09/23 ASTRAZENECA : 23 September 2016 Innovative pancreatic research expands treatment..
09/22 ASTRAZENECA : provides update on cediranib EU marketing authorisation applicatio..
09/22 ASTRAZENECA : Diabetes drug combo shows positive results in late-stage study
09/22 Synairgen Interim Loss Widens As It Continues Development Programmes
More news
Sector news : Pharmaceuticals - NEC
02:13p Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Whose Drug Pipeline Impresses Most? A Rough Comparison Of GlaxoSmithKline And..
09/24 BIOTECH : What's Next For M&A?
09/23 Agenus' Immuno-Oncology Pipeline Has Promise
09/21 Allergan Sparks A Second Liver Disease Craze
09/21 ALLERGAN : Examining The Premiums Paid
Financials ($)
Sales 2016 23 302 M
EBIT 2016 5 501 M
Net income 2016 2 589 M
Debt 2016 11 860 M
Yield 2016 4,29%
P/E ratio 2016 32,89
P/E ratio 2017 29,85
EV / Sales 2016 4,07x
EV / Sales 2017 4,23x
Capitalization 83 018 M
More Financials
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 66,7 $
Spread / Average Target 1,3%
Consensus details
EPS Revisions
More Estimates Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON16.06%322 232
ROCHE HOLDING LTD.-12.41%215 081
NOVARTIS AG-10.14%211 231
PFIZER INC.4.80%204 049
MERCK & CO., INC.18.46%171 858
More Results